To understand JMML development within the stem cell compartment and to identify new therapeutic targets, we characterized histone modifications and chromatin accessibility in the CD34+ cells of five PTPN11-mutated JMML spleen-derived HSPCs (Figure 1A). The gene discussed is CD34; the disease is juvenile myelomonocytic leukemia.